Lyell Immunopharma (LYEL) Other Non-Current Assets (2020 - 2026)

Lyell Immunopharma has reported Other Non-Current Assets for 7 years, with the latest figure at $1.6 million in Q1 2026.

• Quarterly Other Non-Current Assets fell 6.04% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 6.04% YoY) and the FY2025 annual result came in at $1.6 million, down 65.71% from the prior year.
• Other Non-Current Assets held at $1.6 million in Q1 2026 per LYEL's latest filing, from $1.6 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $4.6 million in Q4 2024 and troughed at $279000.0 in Q1 2022.
• A 5-year average of $983411.8 and a median of $286000.0 in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets soared 1527.46% in 2024, then plunged 65.71% in 2025.
• Over 5 years, Other Non-Current Assets stood at $280000.0 in 2022, then climbed by 1.43% to $284000.0 in 2023, then jumped by 1527.46% to $4.6 million in 2024, then slumped by 65.71% to $1.6 million in 2025, then increased by 0.06% to $1.6 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.6 million, $1.6 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.